Day: March 28, 2025

The Annual General Meeting og Iceland Seafood International hf was held, 26th March 2025.  Attached are results of the meeting. AttachmentISI_AGM_26 March 2025 – Results from the meeting

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1993, AS AMENDED (THE “SECURITIES ACT”)) OR ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE US VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. NANTERRE (FRANCE)MARCH 27, 2025 FORVIA PRICES AN INAUGURAL 5-YEAR DOLLAR BOND ISSUANCE OF $500 MILLION SENIOR NOTES FORVIA has priced 500 million U.S. dollars of 8.00% senior notes due 2030. This transaction is the inaugural dollar bond issuance by FORVIA and follows the...

PRESS RELEASE 28 March 2025 – Alstom, a global leader in smart and sustainable mobility, has signed a contract with the Moroccan National Railway Office (ONCF) worth €781 million to supply 18 Avelia Horizon high-speed trains. This order has been recorded in Alstom’s Q4 2024/2025 fiscal year.  The extension of the high-speed line to Marrakech will enhance connectivity for travellers. Alstom’s new double-decker Avelia Horizon trains will significantly reduce travel time between Tangier and Marrakech while minimizing the carbon footprint. Benefiting from over 40 years of experience of high-speed trains in commercial services, Alstom’s Avelia Horizon very high-speed train is the latest generation of double-deck train in the world capable of operating at speeds exceeding 300 km/h. It offers great operational flexibility and ensures...

Syensqo releases 2024 annual integrated report Brussels, Belgium – March 28, 2025 – 08:30 CET Syensqo has published its 2024 annual integrated report today giving its stakeholders a comprehensive and integrated overview of the company’s strategy, business activities and performance for its first year.  The report comprises the company’s financial and extra-financial statements, compliant with the EU Corporate Sustainability Reporting Directive (CSRD), One Planet roadmap progress on Climate, Nature, Growth, and Better Life. The 2024 annual integrated report is posted in the Financials section of the Syensqo website. A European Single Electronic Format (ESEF) as required by EU Regulation 2019/815 is also available for download. ContactsInvestors & Analystsinvestor.relations@syensqo.com Media media.relations@syensqo.com...

APPOINTMENT WITHIN THE SOCIETE GENERALE GROUP Press release Paris, 28 March 2025 Societe Generale announces the appointment of Alexis Kohler as Executive Vice President. He will join the Bank in June 2025 and will be a member of the Group Executive Committee. Reporting to Slawomir Krupa, Chief Executive Officer, Alexis Kohler will have the following responsibilities:As Chairman of Investment Banking, he will be responsible for leading Mergers & Acquisitions, Equity Capital Markets and Acquisition Finance activities, as well as coordinating coverage teams for large clients. He will assist the Chief Executive Officer in implementing transformation programs within the firm. Alexis Kohler will oversee the Group’s General Secretariat and the Human Resources and Communication departments.Alexis Kohler will contribute to the Group’s...

AB “Novaturas” plans to publish regulated and investors related information for the year 2025 on the following dates: 12 05 2025                         Decisions of Annual General Meeting of ShareholdersTill 10 06 2025                    Decisions of Annual General Meeting of Shareholders19 08 2025                         Interim consolidated financial statements for 6 months of 202527 02 2026                         Interim consolidated financial statements for 12 months of 2025 Darius UndzėnasCFO+370 678 05749  

Novaturas announces that due to objective circumstances, the publication date of the audited financial statement for 2024 has been rescheduled. The report is planned to be released on May 12, 2025 (previously scheduled for April 30, 2025). The revised publication date is due to the financial report preparation and audit processes taking longer than initially planned, as well as the company’s commitment to ensuring the quality and accuracy of the reports. About the company The Novaturas Group is a tour operator offering the widest range of travel destinations from the Baltic States. It has been operating in the region for 25 years. The company offers summer and winter recreational, sightseeing, exotic, skiing, workation and group trips to many destinations worldwide. According to unaudited data, in 2024, Novaturas Group recorded revenues...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammation TARRYTOWN, N.Y. and PARIS, March 28, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy. The approval in Japan was based on data from the landmark pivotal BOREAS Phase 3 trial. The trial...

  Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammationParis and Tarrytown, NY, March 28, 2025. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy. The approval in Japan was based on data from the landmark BOREAS phase 3 study. The study evaluated Dupixent added to background...